Acadia Pharmaceuticals (ACAD) PT Raised to $49 at Needham & Company Ahead of NDA Submission
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Acadia Pharmaceuticals (ACAD) PT Raised to $49 at Needham & Company Ahead of NDA Submission
August 6, 2015 4:01 PM EDT
SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in neurological and related central
nervous system disorders, today announced its unaudited financial
results for the second quarter ended June 30, 2015.
ACADIA reported a net loss of $39.4 million, or $0.39 per common share,
for the second quarter of 2015 compared to a net loss of $21.5 million,
or $0.22 per common share, for the second quarter of 2014. Net losses
for the second quarters of 2015 and 2014 included $7.5 million and $4.3
million, respectively, in non-cash... More
August 6, 2015 9:00 AM EDT
SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in neurological and related central
nervous system disorders, today announced the publication of new data
from its ongoing open-label safety extension study, the -015 Study, with
NUPLAZID in patients with Parkinsons disease psychosis (PDP) in the
July 31 online issue of the Journal of the American Medical Directors
Association... More
